Myeloid cell-associated aromatic amino acid metabolism facilitates CNS myelin regeneration

Jingwen Hu,George S. Melchor,Dimitrios Ladakis,Joan Reger,Hee Won Kim,Kelly A. Chamberlain,Nataliia V. Shults,Helena C. Oft,Victoria N. Smith,Lauren M. Rosko,Erqiu Li,Maryna Baydyuk,Meng-Meng Fu,Pavan Bhargava,Jeffrey K. Huang

DOI: https://doi.org/10.1038/s41536-023-00345-9

IF: 14.404

2024-01-02

npj Regenerative Medicine

Abstract:Abstract Regulation of myeloid cell activity is critical for successful myelin regeneration (remyelination) in demyelinating diseases, such as multiple sclerosis (MS). Here, we show aromatic alpha-keto acids (AKAs) generated from the amino acid oxidase, interleukin-4 induced 1 (IL4I1), promote efficient remyelination in mouse models of MS. During remyelination, myeloid cells upregulated the expression of IL4I1. Conditionally knocking out IL4I1 in myeloid cells impaired remyelination efficiency. Mice lacking IL4I1 expression exhibited a reduction in the AKAs, phenylpyruvate, indole-3-pyruvate, and 4-hydroxyphenylpyruvate, in remyelinating lesions. Decreased AKA levels were also observed in people with MS, particularly in the progressive phase when remyelination is impaired. Oral administration of AKAs modulated myeloid cell-associated inflammation, promoted oligodendrocyte maturation, and enhanced remyelination in mice with focal demyelinated lesions. Transcriptomic analysis revealed AKA treatment induced a shift in metabolic pathways in myeloid cells and upregulated aryl hydrocarbon receptor activity in lesions. Our results suggest myeloid cell-associated aromatic amino acid metabolism via IL4I1 produces AKAs in demyelinated lesions to enable efficient remyelination. Increasing AKA levels or targeting related pathways may serve as a strategy to facilitate the regeneration of myelin in inflammatory demyelinating conditions.

cell & tissue engineering,engineering, biomedical

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to promote remyelination by regulating the activities of myeloid cells (such as microglia and macrophages) in demyelinating diseases such as multiple sclerosis (MS). Specifically, the study focused on an enzyme named IL4I1, which is expressed in myeloid cells and can produce aromatic α - keto acids (AKAs), and these metabolites play an important role in remyelination. The paper explored the following points:

1. **The role of IL4I1 in myeloid cells**: The study found that during the remyelination process, the expression of IL4I1 in myeloid cells was up - regulated. Conditional knockout of the IL4I1 gene in myeloid cells led to a decrease in the efficiency of remyelination.

2. **The role of AKAs in remyelination**: The AKAs produced by IL4I1 were decreased in demyelinating lesions, especially in the progressive stage of MS patients. Oral supplementation of AKAs can reduce the inflammatory response and promote the maturation of oligodendrocytes, thereby enhancing remyelination.

3. **The influence of AKAs on the metabolism of myeloid cells**: Through transcriptome analysis, the study found that after AKAs treatment, the metabolic pathways of myeloid cells were changed, especially the aryl hydrocarbon receptor (AhR) signaling pathway was activated. AhR is an important transcription factor involved in the regulation of immune responses.

4. **Clinical relevance**: The study also found that the levels of AKAs in the serum of MS patients were decreased, especially in patients in the progressive stage. This indicates that the decrease in AKAs levels may be related to the progression of MS.

In summary, this paper aims to reveal the key roles of IL4I1 and its metabolite AKAs in the remyelination process, providing a theoretical basis for further development of treatment strategies for demyelinating diseases such as MS.